FASN is responsible for synthesizing palmitate. In tumor cells, and some virus infected cells, palmitate derived from FASN is:
FASN as a therapeutic target in oncology is supported by a number of different observations:
FASN, a well-credentialed target in oncology, has long been a target of interest in the pharmaceutical industry. Our internal medicinal chemistry team has created FASN inhibitors that are orally available, selective, potent and reversible. Based on these characteristics, we have advanced our lead product candidate TVB-2640 as the first-in-class FASN inhibitor into a Phase 1 clinical trial. We have established the preliminary safety profile, defined the maximally tolerated dose (MTD) and demonstrated target engagement in patients. We are now expanding the trial to enroll multiple cohorts of patients with specific tumor types.